Asciminib for chronic myeloid leukaemia: Next questions-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Asciminib for chronic myeloid leukaemia: Next questions

Published:2022-06-21 Issue:3 Volume:199 Page:322-331
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Shanmuganathan Naranie¹²³⁴⁵^ORCID,Hughes Timothy P.¹³⁵^ORCID

Affiliation:

1. Department of Haematology Royal Adelaide Hospital and SA Pathology Adelaide South Australia Australia

2. Department of Genetics and Molecular Pathology and Centre for Cancer Biology SA Pathology Adelaide South Australia Australia

3. Precision Cancer Medicine Theme South Australian Health and Medical Research Institute (SAHMRI) Adelaide South Australia Australia

4. Clinical and Health Sciences University of South Australia Adelaide South Australia Australia

5. Adelaide Medical School University of Adelaide Adelaide South Australia Australia

Funder

National Health and Medical Research Council

Department of Health, Australian Government

Publisher

Wiley

Subject

Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bjh.18323

Reference44 articles.

1. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia

2. Chronic Myeloid Leukemia — Advances in Biology and New Approaches to Treatment

3. Imatinib Compared with Interferon and Low-Dose Cytarabine for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia

4. Nilotinib versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia

5. Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION)

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real-World Disproportionality Analysis of the Food and Drug Administration Adverse Event Reporting System Database for Asciminib;Oncology;2024-08-05

2. Asciminib in treating chronic myeloid leukaemia;Onkologie;2024-06-24

3. A safety review of tyrosine kinase inhibitors for chronic myeloid leukemia;Expert Opinion on Drug Safety;2024-04

4. Effects of bortezomib on ponatinib-resistant Philadelphia chromosome-positive cells;Leukemia & Lymphoma;2024-02

5. Italian Physicians’ Perceptions about the Role of Asciminib in Later Lines Chronic Myeloid Leukemia in Clinical Practice: A GIMEMA Survey;Journal of Clinical Medicine;2023-08-13

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3